205 related articles for article (PubMed ID: 28073228)
21. Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients.
Descamps O; Tomassini JE; Lin J; Polis AB; Shah A; Brudi P; Hanson ME; Tershakovec AM
Atherosclerosis; 2015 Jun; 240(2):482-9. PubMed ID: 25913444
[TBL] [Abstract][Full Text] [Related]
22. Statin intolerance: an updated, narrative review mainly focusing on muscle adverse effects.
Li JJ; Liu HH; Wu NQ; Yeo KK; Tan K; Ako J; Krittayaphong R; Tan RS; Aylward PE; Baek SH; Dalal J; Fong AYY; Li YH; O'Brien RC; Lim TSE; Koh SYN; Scherer DJ; Tada H; Kang V; Butters J; Nicholls SJ
Expert Opin Drug Metab Toxicol; 2020 Sep; 16(9):837-851. PubMed ID: 32729743
[TBL] [Abstract][Full Text] [Related]
23. Novel strategies for managing dyslipidemia: treatment beyond statins.
Ling H; Burns TL; Hilleman DE
Postgrad Med; 2012 Nov; 124(6):43-54. PubMed ID: 23322138
[TBL] [Abstract][Full Text] [Related]
24. Evolocumab: A Review in Hyperlipidemia.
Keating GM
Am J Cardiovasc Drugs; 2016 Feb; 16(1):67-78. PubMed ID: 26643308
[TBL] [Abstract][Full Text] [Related]
25. [Combined treatment: regimens, indications and safety profile].
Muñiz Grijalvo O; Villar Ortiz J
Clin Investig Arterioscler; 2013; 25(3):140-5. PubMed ID: 23880257
[TBL] [Abstract][Full Text] [Related]
26. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel.
Banach M; Rizzo M; Toth PP; Farnier M; Davidson MH; Al-Rasadi K; Aronow WS; Athyros V; Djuric DM; Ezhov MV; Greenfield RS; Hovingh GK; Kostner K; Serban C; Lighezan D; Fras Z; Moriarty PM; Muntner P; Goudev A; Ceska R; Nicholls SJ; Broncel M; Nikolic D; Pella D; Puri R; Rysz J; Wong ND; Bajnok L; Jones SR; Ray KK; Mikhailidis DP
Expert Opin Drug Saf; 2015 Jun; 14(6):935-55. PubMed ID: 25907232
[TBL] [Abstract][Full Text] [Related]
27. [Up to date lipid lowering treatment].
Paragh G; Karádi I
Orv Hetil; 2016 Jul; 157(31):1219-23. PubMed ID: 27476517
[TBL] [Abstract][Full Text] [Related]
28. Hypolipidemic Drugs and Diabetes Mellitus-Mechanisms and Data From Genetic Trials.
Filippatos TD; Panagiotopoulou T; Tzavella E; Elisaf MS
J Cardiovasc Pharmacol Ther; 2018 May; 23(3):187-191. PubMed ID: 29409336
[TBL] [Abstract][Full Text] [Related]
29. Red yeast rice may be a statin substitute. People who are statin-intolerant due to side effects of muscle pain may benefit from this ancient Asian dietary and medicinal staple.
Duke Med Health News; 2009 Sep; 15(9):1-2. PubMed ID: 19785077
[No Abstract] [Full Text] [Related]
30. Impact of Ezetimibe Alone or in Addition to a Statin on Plasma PCSK9 Concentrations in Patients with Type 2 Diabetes and Hypercholesterolemia: A Pilot Study.
Miyoshi T; Nakamura K; Doi M; Ito H
Am J Cardiovasc Drugs; 2015 Jun; 15(3):213-9. PubMed ID: 25896669
[TBL] [Abstract][Full Text] [Related]
31. Statin intolerance.
Laufs U; Scharnagl H; März W
Curr Opin Lipidol; 2015 Dec; 26(6):492-501. PubMed ID: 26780003
[TBL] [Abstract][Full Text] [Related]
32. Neuromuscular complications of statins.
Ahn SC
Phys Med Rehabil Clin N Am; 2008 Feb; 19(1):47-59, vi. PubMed ID: 18194749
[TBL] [Abstract][Full Text] [Related]
33. 2019 Taiwan Society of Lipids and Atherosclerosis expert consensus statement on statin intolerance.
Chien SC; Chen PS; Huang YH; Tang SC; Li YH; Yeh HI
J Formos Med Assoc; 2019 Oct; 118(10):1385-1392. PubMed ID: 30584005
[TBL] [Abstract][Full Text] [Related]
34. Statin intolerance.
Ahmad Z
Am J Cardiol; 2014 May; 113(10):1765-71. PubMed ID: 24792743
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial.
Moriarty PM; Thompson PD; Cannon CP; Guyton JR; Bergeron J; Zieve FJ; Bruckert E; Jacobson TA; Kopecky SL; Baccara-Dinet MT; Du Y; Pordy R; Gipe DA;
J Clin Lipidol; 2015; 9(6):758-769. PubMed ID: 26687696
[TBL] [Abstract][Full Text] [Related]
36. Risk assessement and its management: from SCORE to statins, ezetimibe to PCSK inhibitors.
Lüscher TF
Eur Heart J; 2017 Aug; 38(29):2233-2236. PubMed ID: 28810720
[No Abstract] [Full Text] [Related]
37. Reducing CV risk in diabetes: An ADA update.
Skolnik N; Jaffa FM; Kalyani RR; Johnson E; Shubrook JH
J Fam Pract; 2017 May; 66(5):300-308. PubMed ID: 28459890
[TBL] [Abstract][Full Text] [Related]
38. Algorithms to Identify Statin Intolerance in Medicare Administrative Claim Data.
Colantonio LD; Kent ST; Huang L; Chen L; Monda KL; Serban MC; Manthripragada A; Kilgore ML; Rosenson RS; Muntner P
Cardiovasc Drugs Ther; 2016 Oct; 30(5):525-533. PubMed ID: 27389413
[TBL] [Abstract][Full Text] [Related]
39. Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance.
Koskinas K; Wilhelm M; Windecker S
Swiss Med Wkly; 2016; 146():w14333. PubMed ID: 27400448
[TBL] [Abstract][Full Text] [Related]
40. [Statin myopathy--rarity or reality?].
Pella D
Vnitr Lek; 2010 Sep; 56(9 Suppl):972-6. PubMed ID: 21137170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
